Coherus Oncology, Inc. announced an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), scheduled for November 5-9, 2025. The abstract, titled 'CHS-114, an anti-CCR8 cytolytic monoclonal antibody demonstrates selective intratumoral Treg depletion and favorable immune remodeling in participants with advanced solid tumors,' will highlight key findings.
This presentation will provide further scientific validation for CHS-114, an anti-CCR8 cytolytic monoclonal antibody, and its ability to selectively deplete intratumoral regulatory T cells (Tregs). The data supports the concept of favorable immune remodeling within the tumor microenvironment, which is crucial for effective anti-cancer responses.
Additionally, CHS-114 will be featured in the 'Targets for Cancer IO: A Deep Dive' live webinar series, focusing on the novel therapeutic target C-C chemokine receptor 8 (CCR8). This continued scientific discourse underscores the potential of CHS-114 as a promising new strategy to treat various cancers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.